Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss
- PMID: 20171173
- PMCID: PMC2847063
- DOI: 10.1016/j.bbrc.2010.02.080
Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss
Abstract
There is strong clinical evidence that implicates tenofovir in the loss of bone mineral density during treatment of human immunodeficiency virus infection. In this study, we sought to test the hypothesis that tenofovir treatment of osteoblasts causes changes in the gene expression profile that would impact osteoblast function during bone formation. Primary osteoblasts were isolated and then treated with the tenofovir prodrug, tenofovir disoproxil fumarate (TDF). Total RNA from TDF-treated and untreated osteoblasts were extracted and used for microarray analysis to assess TDF-associated changes in the gene expression profile. Strikingly, the changes in gene expression profiles involved in cell signaling, cell cycle and amino acid metabolism, which would likely impact osteoblast function in bone formation. Our findings demonstrate for the first time that tenofovir treatment of primary osteoblasts results in gene expression changes that implicate loss of osteoblast function in tenofovir-associated bone mineral density loss.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Figures


Similar articles
-
Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.Biochem Biophys Res Commun. 2010 Jan 15;391(3):1324-9. doi: 10.1016/j.bbrc.2009.12.039. Epub 2009 Dec 21. Biochem Biophys Res Commun. 2010. PMID: 20026012 Free PMC article.
-
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.J Clin Endocrinol Metab. 2013 Apr;98(4):1659-66. doi: 10.1210/jc.2012-3686. Epub 2013 Feb 22. J Clin Endocrinol Metab. 2013. PMID: 23436922 Clinical Trial.
-
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.Pediatrics. 2006 Sep;118(3):e711-8. doi: 10.1542/peds.2005-2525. Epub 2006 Aug 21. Pediatrics. 2006. PMID: 16923923 Clinical Trial.
-
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. Antiviral Res. 2016. PMID: 26640223 Review.
-
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.Drugs. 2014 Jan;74(1):75-97. doi: 10.1007/s40265-013-0158-4. Drugs. 2014. PMID: 24338165 Review.
Cited by
-
Human immunodeficiency virus envelope protein Gp120 induces proliferation but not apoptosis in osteoblasts at physiologic concentrations.PLoS One. 2011;6(9):e24876. doi: 10.1371/journal.pone.0024876. Epub 2011 Sep 12. PLoS One. 2011. PMID: 21931863 Free PMC article.
-
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.Clin Infect Dis. 2012 Apr;54(7):1013-25. doi: 10.1093/cid/cir968. Epub 2012 Jan 19. Clin Infect Dis. 2012. PMID: 22267714 Free PMC article. Clinical Trial.
-
The anti-HIV drug abacavir stimulates β-catenin activity in osteoblast lineage cells.JBMR Plus. 2024 Mar 19;8(5):ziae037. doi: 10.1093/jbmrpl/ziae037. eCollection 2024 May. JBMR Plus. 2024. PMID: 38590756 Free PMC article.
-
Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B.Ther Adv Infect Dis. 2021 Feb 5;8:2049936120985954. doi: 10.1177/2049936120985954. eCollection 2021 Jan-Dec. Ther Adv Infect Dis. 2021. PMID: 33614029 Free PMC article. Review.
-
Continued Interest and Controversy: Vitamin D in HIV.Curr HIV/AIDS Rep. 2018 Jun;15(3):199-211. doi: 10.1007/s11904-018-0401-4. Curr HIV/AIDS Rep. 2018. PMID: 29713871 Free PMC article. Review.
References
-
- Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr. 2002;29:450–4. - PubMed
-
- Vigano A, Mora S. Adverse effects of antiretroviral therapy: focus on bone density. Expert Opin Drug Saf. 2004;3:199–208. - PubMed
-
- Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39–48. - PubMed
-
- Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical